- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04295239
Non-invasive Monitoring of Cerebral Autoregulation in Perioperative Neonatal Cardiac Surgery (NEMOCARD)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nantes, France
- CHU de Nantes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any newborn (0-28 days) with congenital heart disease, hospitalized in the preoperative period at the Nantes University Hospital, for whom a decision is made to perform an operation under extracorporeal circulation, suitable to be transported for an MRI without risk, advice taken from the treating team.
Exclusion Criteria:
- emergency cardiac surgery
- Preoperative extracorporeal assistance
- Preoperative intubation
- Preoperative administration of inotropes
- Pre-operative instability contra-indicating pre-operative MRI
- Dependence on a pace maker contra-indicating MRI Imaging.
- Parental consent refusal
- Non-affiliation to a health security insurance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MRI
Pre-operative AND post-operative MRI
|
Pre and Post operative MRI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
determine the association between time spent outside individually determined cerebral autoregulation limits and the development of brain lesions suggestive of low brain output.
Time Frame: 6 weeks after cardiac surgery
|
duration of period outside cerebral autoregulation limits, Number, size and extent of new lesions on post-operative MRI. Patients will be classified into 2 categories according to whether or not there are new lesions on MRI. The lesions retained will be infarcts, white matter lesions and intraparenchymal hemorrhages, classified according to the Magnetic Resonance Imaging Abnormality Scoring System. |
6 weeks after cardiac surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
describe predictive factors of postoperative encephalopathy
Time Frame: day 1 (cardiac surgery)
|
duration of extra-corporal circulation,
|
day 1 (cardiac surgery)
|
|
describe predictive factors of postoperative encephalopathy
Time Frame: day 1 (cardiac surgery)
|
duration of aortic clamp
|
day 1 (cardiac surgery)
|
|
describe predictive factors of postoperative encephalopathy
Time Frame: day 1 (cardiac surgery)
|
duration of selective cerebral perfusion,
|
day 1 (cardiac surgery)
|
|
describe predictive factors of postoperative encephalopathy
Time Frame: day 1 (cardiac surgery)
|
duration of hypothermia deepness
|
day 1 (cardiac surgery)
|
|
describe predictive factors of postoperative encephalopathy
Time Frame: day 1 (cardiac surgery)
|
duration of critical NIRS
|
day 1 (cardiac surgery)
|
|
describe predictive factors of postoperative encephalopathy
Time Frame: day 1 (cardiac surgery)
|
duration of critical median arterial pression (PAM)
|
day 1 (cardiac surgery)
|
|
describe association between time spent outside autoregulation limits and the occurrence of postoperative encephalopathy defined by clinical and encephalographic criteria.
Time Frame: 6 weeks after cardiac surgery
|
duration of period outside cerebral autoregulation limits, Standardized clinical examination according to Amiel Tison at hospital discharge.
|
6 weeks after cardiac surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC19_0413
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.